10-Q: Cytek Biosciences Reports Q3 Loss Amid Revenue Shifts

Cytek Biosciences reported a net loss of $5.5 million for the third quarter of 2025, driven by increased operating expenses and a decline in product revenue, despite growth in service revenue.

Summary

• Net loss for the three months ended September 30, 2025, was $5.5 million, compared to net income of $0.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $22.5 million, compared to a net loss of $15.7 million for the same period in 2024.
• Total revenue for the three months ended September 30, 2025, increased by 2% to $52.3 million, primarily due to higher service revenue.
• Total revenue for the nine months ended September 30, 2025, decreased by 3% to $139.4 million, mainly due to lower instrument sales to academic and government customers in EMEA and the United States.
• Product revenue decreased by 4% to $38.1 million for the three months and by 10% to $97.6 million for the nine months ended September 30, 2025.
• Service revenue increased by 19% to $14.2 million for the three months and by 20% to $41.7 million for the nine months ended September 30, 2025.
• Gross profit margin declined to 53% for the three months and 51% for the nine months ended September 30, 2025, from 56% and 54% respectively in 2024, due to higher labor, travel, material, and overhead costs.
• General and administrative expenses increased significantly by 47% to $16.1 million for the three months and by 25% to $42.6 million for the nine months ended September 30, 2025, primarily due to ongoing patent litigation expenses and a $0.7 million write-off of deferred offering costs.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $3.9 million, a significant shift from $23.4 million provided by operating activities in the prior year.
• The company repurchased 3,292,588 shares of common stock for $15.1 million during the nine months ended September 30, 2025, under a $50 million program expiring December 31, 2025, with $35.0 million remaining.

Sentiment

Score: 3

Explanation: The company reported increased net losses and a significant shift to negative operating cash flow, driven by declining product revenue and rising operating expenses, particularly general and administrative costs due to litigation and write-offs. While service revenue showed growth and new products were launched, the overall financial performance indicates a challenging period with unresolved internal control issues and external risks like export controls and tariffs.

Positives

• Service revenue grew by 19% for the quarter and 20% for the nine months, indicating a growing installed base and recurring revenue stream.
• The Cytek Aurora Evo system was launched in May 2025, expanding the product portfolio.
• The Northern Lights-CLC system received CE Marking and EU registration, enabling clinical use in Europe, and is registered as a Class II IVD in China.
• The company maintains a strong cash and short-term investments balance of $261.7 million as of September 30, 2025.
• The share repurchase program demonstrates a commitment to returning capital to shareholders and minimizing dilution.

Negatives

• The company reported a net loss of $5.5 million for the quarter and $22.5 million for the nine months, a deterioration from prior periods.
• Product revenue decreased by 4% for the quarter and 10% for the nine months, primarily due to lower instrument sales in EMEA and the United States.
• Gross profit margins declined across both product and service segments due to increased costs (labor, travel, materials, overhead, tariffs).
• General and administrative expenses saw a substantial increase (47% for the quarter, 25% for nine months) driven by patent litigation and a $0.7 million write-off of deferred offering costs.
• Net cash flow from operating activities turned negative, using $3.9 million for the nine months ended September 30, 2025, compared to providing $23.4 million in the prior year.
• Interest income decreased significantly by 60% for the quarter and 61% for the nine months, due to lower average cash balances and a lower interest rate environment.
• Identified material weaknesses in internal control over financial reporting for the year ended December 31, 2024, which were not yet fully remediated as of September 30, 2025.

Risks

• Limited operating history and experience marketing and selling products, making future performance difficult to predict.
• High dependence on a limited number of product offerings (Cytek Aurora, Northern Lights, Cytek Aurora CS, Cytek Aurora Evo systems), which have substantial sales cycles and are prone to quarterly fluctuations.
• Reliance on single and sole-source suppliers for key components, with potential for supply interruptions, increased costs, and delays in qualifying alternative suppliers.
• Inability to accurately forecast customer demand and manage inventory, potentially leading to write-downs or shortages.
• Exposure to business, regulatory, political, operational, financial, and economic risks associated with international operations and expansion.
• Adverse effects from tariffs or other government trade policies, including reduced demand for products and increased manufacturing costs.
• Subject to governmental export controls and sanctions programs, including new U.S. license requirements (January 15, 2025) impacting exports of certain products to countries including China, which may negatively affect sales, manufacturing, and R&D.
• Limited experience manufacturing products at high-quality commercial quantities, posing risks of quality issues, defects, errors, or recalls.
• Dependence on adoption of products by academic and government institutions, CROs, pharmaceutical companies, and clinical laboratories, which may be unwilling to change current practices.
• Significant reliance on research and development spending by academic and government-owned institutions, a reduction in which could limit demand.
• Reliance on distributors for sales in certain international geographies, with risks if they do not perform adequately or effectively.
• Highly competitive market for cell analysis technologies and life sciences tools, potentially hindering revenue growth or profitability.
• Future success depends on the ability to develop and successfully introduce new and enhanced products, which is a lengthy and complex process with no guarantee of commercial viability.
• Products may contain defects not detected until deployed, increasing costs and reducing net sales, and potentially leading to product liability suits.
• Potential negative impact from future acquisitions, joint ventures, or investments, including debt, contingent liabilities, or write-offs.
• Risks related to shipping arrangements, including damages, losses, delays, and increased costs.
• Inability to successfully expand commercial operations, including hiring and retaining qualified sales, technical, and customer support staff.
• Failure to expand or leverage peer-reviewed articles or increase brand awareness could adversely affect demand.
• Difficulties in managing organizational growth, including strain on infrastructure and potential inefficiencies.
• Material weaknesses in internal control over financial reporting, which, if not remediated, could impact financial reporting accuracy and timeliness.
• Need to raise additional capital in the future, which may not be available on acceptable terms or could dilute existing stockholders.
• Significant fluctuations in operating results, making future performance difficult to predict.
• Market sizes for products may be smaller than estimated, impairing sales growth.
• Potential for products to become subject to more onerous regulation by the FDA or other regulatory agencies, increasing costs and delaying sales.
• Ongoing regulatory obligations and review, with penalties for non-compliance.
• Products may be subject to recalls, impacting reputation and sales.
• Misuse or off-label use of products could harm reputation or result in liability suits.
• Subject to stringent and changing U.S. and foreign data privacy and security laws, with potential for investigations, fines, and business disruption.
• Subject to U.S. and foreign anti-corruption and anti-money laundering laws, with potential for criminal liability.
• Disruptions at government agencies (FDA, SEC) could hinder their ability to perform functions on which the business relies.
• Failure to comply with U.S. federal and state fraud and abuse and other healthcare laws could lead to substantial penalties.
• Misconduct by employees, contractors, or partners could harm the business.
• Inability to obtain and maintain patent or other intellectual property protection, or if protection is not broad enough, competitors could commercialize similar products.
• Patents could be found invalid or unenforceable if challenged.
• Reliance on trademarks and trade names, which if not adequately protected, could harm brand recognition.
• Ineffective efforts to enforce or protect proprietary rights, leading to substantial costs.
• Limited foreign intellectual property rights outside the U.S., selected countries in the European Union, Japan, and China.
• Changes in U.S. patent law could diminish the value of patents.
• Third-party claims of intellectual property infringement, misappropriation, or other violation.
• Lawsuits to protect or enforce patents and other intellectual property rights could be expensive and unsuccessful.
• Claims that employees, consultants, or advisors wrongfully used or disclosed trade secrets.
• Inability to protect the confidentiality of trade secrets.
• Failure of a key information technology system, process, or site could have an adverse effect on the business.
• Use of open source software could compromise ability to offer services and lead to litigation.
• Stock price may continue to be volatile, and stockholders may not be able to resell shares at or above the price they paid.
• Broad discretion in the use of cash, which may not yield a return.
• Substantial future sales of shares of common stock or securities convertible into common stock will result in additional dilution and could cause the market price to decline.
• Concentration of ownership of common stock among executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• No intention to pay dividends for the foreseeable future, meaning ability to achieve a return depends on appreciation in stock price.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Exclusive forum provisions in charter documents and bylaws could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Estimates or judgments relating to critical accounting policies, if based on assumptions that change or prove incorrect, could cause operating results to fall below expectations.
• Incurred and will continue to incur increased costs as a result of operating as a public company.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of common stock.
• If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about the business, common stock price and trading volume could decline.
• Ability to use net operating losses (NOLs) to offset future taxable income may be subject to certain limitations.
• Changes in effective tax rate or tax liability may have an adverse effect on results of operations.
• Changes and uncertainties in the tax system in the countries of operation could materially adversely affect financial condition and results of operations.

Future Outlook

The company anticipates continuing to expend significant cash in the foreseeable future on research and development of product offerings, commercialization of new products and services, and expansion into new markets. Expenses are expected to increase substantially to attract and retain qualified personnel, invest in infrastructure, support R&D, expand geographically, protect intellectual property, and make strategic investments. Management believes existing cash and anticipated cash flows from operations will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months.

Management Comments

• "Total revenue for the three months ended September 30, 2025 increased compared to total revenue for the three months ended September 30, 2024, due to higher service revenue from a larger installed base of instruments compared to a year ago, partially offset by lower product revenue resulting from lower instrument sales in EMEA."
• "The decrease in total revenue for the nine months ended September 30, 2025, compared to total revenue for the nine months ended September 30, 2024 was due to lower instrument sales to academic and government customers in EMEA and the United States."
• "We intend to continue to make significant investments in research and development in the future."
• "We expect to continue to invest in our commercial infrastructure through hiring additional employees with strong scientific and technical backgrounds to support growth in our instrument sales as well as our planned expansion of reagents offerings and panel design capabilities."
• "We expect our expenses will increase substantially in connection with our ongoing activities..."
• "Based on our current business plan, we believe our existing cash and cash equivalents and anticipated cash flows from operations will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months from the date of this Quarterly Report on Form 10-Q."

Industry Context

The company operates in the highly competitive cell analysis and life sciences tools markets, facing established and early-stage companies. The market is characterized by significant technological enhancements and evolving regulatory standards. Demand is influenced by R&D spending by academic and government institutions, which can be subject to budgetary constraints. New U.S. export controls on high-parameter flow cytometers and cell sorters to certain countries, including China, are noted as a significant industry-specific challenge. The company is expanding into adjacent markets like immunotherapy, immuno-oncology, and clinical diagnostics.

Comparison to Industry Standards

• The company's FSP platform aims to provide a higher level of multiplexing with exquisite sensitivity, more flexibility, and increased efficiency at a lower cost for performance compared to other technologies in the market.
• The Northern Lights-CLC system has received CE Marking and EU registration, and is registered as a Class II IVD in China, indicating compliance with specific international medical device standards for clinical use, which is a competitive advantage in those regions.
• The company's products are primarily 'research use only' (RUO) in the U.S., contrasting with competitors who may have broader clinical diagnostic approvals.
• Competitors mentioned include Agilent Technologies, Beckman Coulter (Danaher Corporation), Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Standard BioTools Inc., Miltenyi Biotec, Sony Biotechnology (Sony Corporation), and Thermo Fisher Scientific.

Corporate Governance

Legal Proceedings

• Becton, Dickinson, and Company (BD) lawsuit (filed Feb 13, 2018) alleging trade secret misappropriation and copyright infringement. Settled Oct 6, 2020, with mutual release of claims, non-exclusive license from BD, and payments including a low single-digit royalty for ten years on certain products.
• Beckman Coulter, Inc. lawsuit (filed Aug 14, 2024) in federal court in Delaware, alleging infringement of U.S. Patent Nos. 10,330,582 and 11,703,443 by Cytek Aurora, Cytek Aurora CS, Northern Lights, and Northern Lights-CLC products.
• Company filed counterclaim against Beckman Coulter for false marking on October 7, 2024.
• Beckman Coulter filed first amended complaint on January 9, 2025, adding U.S. Patent Nos. 12,174,106 and 12,174,107.
• Company filed answer to first amended complaint and counterclaim against Beckman Coulter for false patent marking on February 6, 2025.
• Claim construction hearings held on August 21, 2025, and September 17, 2025, where the court ordered Beckman Coulter to narrow asserted claims, resulting in the dropping of all claims from U.S. Patent No. 12,174,106.
• Briefing on dispositive motions scheduled for March and April 2026, with a trial scheduled for August 17, 2026.

Stakeholder Impact

• Shareholders face dilution risk from future equity offerings, potential decline in stock price due to volatile operating results, material weaknesses in internal controls, and ongoing litigation. They may benefit from the share repurchase program.
• Employees are impacted by stock-based compensation plans, 401(k) retirement savings plan, and potential for increased hiring in R&D and commercial infrastructure. There is a risk of losing valuable employees due to intense competition for skilled personnel.
• Customers benefit from new product launches (Cytek Aurora Evo) and expanded clinical approvals (Northern Lights-CLC in EU/China). Risks include product defects, delays in product delivery, and potential impact from export controls and tariffs.
• Suppliers face continued reliance on single and sole-source suppliers, with risks of supply interruptions and changes in trade policies affecting costs.
• Creditors are impacted by the company's financial performance, liquidity, and debt obligations (Wuxi Loan, Bank of China, Bank of Ningbo credit agreements).

Next Steps

• Continue to make significant investments in research and development.
• Invest in commercial infrastructure by hiring additional employees to support instrument sales and expand reagent offerings.
• Continue to invest in sales, marketing, and business development globally.
• Continue efforts to remediate identified material weaknesses in internal control over financial reporting.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Monitor new accounting pronouncements issued by the FASB.
• Vigorously defend against the Beckman Coulter patent infringement lawsuit and pursue the counterclaim.
• Reassess approach to manage foreign currency risk as international operations grow.
• Continue to pursue any required regulatory approvals for clinical use for products in the United States.
• Continue to generate supporting publications and data to drive adoption of FSP solutions.

Key Dates

Recommendation

The company is experiencing significant financial headwinds, including increased net losses, declining product revenue, negative operating cash flow, and rising G&A expenses. While service revenue growth and new product launches offer some positive momentum, the identified material weaknesses in internal controls and ongoing patent litigation introduce considerable uncertainty and risk. The share repurchase program provides some support for shareholders, but the overall financial performance and operational challenges suggest a 'hold' recommendation until there is clearer evidence of sustained profitability, successful remediation of internal control issues, and resolution of key legal and geopolitical risks.

Keywords

Cytek Biosciences, CTKB, Quarterly Report, Financial Results, Cell Analysis, Flow Cytometry, Full Spectrum Profiling, FSP Technology, Biomedical Research, Clinical Applications, Product Revenue, Service Revenue, Net Loss, Operating Expenses, Research and Development, Sales and Marketing, General and Administrative, Gross Margin, Share Repurchase, Patent Litigation, Internal Controls, Export Controls, Tariffs, OBBBA, SEC Filing